Overview of personalized medicine in the disease genomic era
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Sir William Osler (1849-1919) recognized that “variability is the law of life, and as no two faces are the same, so no two bodies are alike, and no two individuals react alike and behave alike under the abnormal conditions we know as disease”. Accordingly, the traditional methods of medicine are not always best for all patients. Over the last decade, the study of genomes and their derivatives (RNA, protein and metabolite)has rapidly advanced to the point that genomic research now serves as the basis for many medical decisions and public health initiatives. Genomic tools such as sequence variation,transcription and, more recently, personal genome sequencing enable the precise prediction and treatment of disease. At present,DNA-based risk assessment for common complex diseases,application of molecular signatures for cancer diagnosis and prognosis, genome-guided therapy, and dose selection of therapeutic drugs are the important issues in personalized medicine. In order to make personalized medicine effective,these genomic techniques must be standardized and integrated into health systems and clinical workflow. In addition, full application of personalized or genomic medicine requires dramatic changes in regulatory and reimbursement policies as well as legislative protection related to privacy. This review aims to provide a general overview of these topics in the field of personalized medicine.
Abstract
Sir William Osler (1849-1919) recognized that “variability is the law of life, and as no two faces are the same, so no two bodies are alike, and no two individuals react alike and behave alike under the abnormal conditions we know as disease”. Accordingly, the traditional methods of medicine are not always best for all patients. Over the last decade, the study of genomes and their derivatives (RNA, protein and metabolite)has rapidly advanced to the point that genomic research now serves as the basis for many medical decisions and public health initiatives. Genomic tools such as sequence variation,transcription and, more recently, personal genome sequencing enable the precise prediction and treatment of disease. At present,DNA-based risk assessment for common complex diseases,application of molecular signatures for cancer diagnosis and prognosis, genome-guided therapy, and dose selection of therapeutic drugs are the important issues in personalized medicine. In order to make personalized medicine effective,these genomic techniques must be standardized and integrated into health systems and clinical workflow. In addition, full application of personalized or genomic medicine requires dramatic changes in regulatory and reimbursement policies as well as legislative protection related to privacy. This review aims to provide a general overview of these topics in the field of personalized medicine.
참고문헌 (24)
- Xing, J., "Toward a more uniform sampling of human genetic diversity: a survey of worldwide populations by high-density genotyping" (2010), Genomics, (in press).
- Ku, C. S., "The discovery of human genetic variations and their use as disease markers: past, present and future", J. Hum. Genet., 55, pp.403~415 (2010)
- Manolio, T. A., "A HapMap harvest of insights into the genetics of common disease", J. Clin. Invest., 118, pp.1590~1605 (2008)
- Abrahams, E., "The personalized medicine coalition: goals and strategies", Am. J. Pharmacogenomics, 5, pp.345~355 (2005)
- Heikes, K. E., "Diabetes risk calculator: a simple tool for detecting undiagnosed diabetes and pre-diabetes", Diabetes Care, 31, pp.1040~1045 (2008)
- Liu, J., "Decision tools in healthcare: focus on the problem, not the solution", BMC Med. Inform. Decis. Mak., 6, pp.4~ (2006)
- Hariri, S., "Evaluation of family history as a risk factor and screening tool for detecting undiagnosed diabetes in a nationally representative survey population", Genet. Med., 8, pp.752~759 (2006)
- Feero, W. G., "New standards and enhanced utility for family health history information in the electronic health record: an update from the American Health Information Community's Family Health History Multi-Stakeholder Workgroup", J. Am. Med. Inform. Assoc., 15, pp.723~728 (2008)
- Willard, H., "Organization, variation, and expression of the human genome as a foundation of genomic and personalized medicine; in Genomics and personalized medicine", pp.4~22 (2009), Elsevier
- Hawkins, R. D., "Next-generation genomics: an integrative approach", Nat. Rev. Genet., 11, pp.476~486 (2010)
- Carenini, M., "ReMINE: an ontology-based risk management platform", Stud. Health Technol. Inform., 148, pp.32~42 (2009)
- Huang, E., "Breast cancer and genomic medicine; in Genomics and personalized medicine", pp.869~878 (2009), Elsevier
- Wiesner, G., "Colorectal cancer; in Genomics and personalized medicine", pp.879~897 (2009), Elsevier
- Dave, S. S, "Molecular diagnosis of Burkitt's lymphoma", N. Engl. J. Med., 354, pp.2431~2442 (2006)
- Voora, D., "The pharmacogenetics of coumarin therapy", Pharmacogenomics, 6, pp.503~513 (2005)
- Ross, J. S., "Targeted therapies for cancer 2004", Am. J. Clin. Pathol., 122, pp.598~609 (2004)
- Metzker, M. L., "Sequencing technologies - the next generation", Nat. Rev. Genet., 11, pp.31~46 (2010)
- Service, R. F., "Gene sequencing. The race for the $1,000 genome", Science, 311, pp.1544~1546 (2006)
- Hunter, D. J., "Letting the genome out of the bottle--will we get our wish?", N. Engl. J. Med., 358, pp.105~107 (2008)
- Clifton, J. M., "The Genetic Information Nondiscrimination Act 2008: what clinicians should understand", J. Am. Acad. Nurse Pract., 22, pp.246~249 (2010)
- Vastag, B., "New clinical trials policy at FDA", Nat. Biotechnol., 24, pp.1043~ (2006)
- Botkin, J. R., "Outcomes of interest in evidence-based evaluations of genetic tests", Genet. Med., 12, pp.228~235 (2010)
- Batchelder, K., "A change in the market--investing in diagnostics", Nat. Biotechnol., 24, pp.922~926 (2006)
- Ginsburg, G. S., "Genomic and personalized medicine: foundations and applications", Transl. Res., 154, pp.277~287 (2009)